Zacks: Brokerages Anticipate Dynavax Technologies Co. (DVAX) to Post -$0.61 EPS
Wall Street brokerages forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will report earnings of ($0.61) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dynavax Technologies’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.64). Dynavax Technologies reported earnings of ($0.63) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.2%. The firm is scheduled to announce its next quarterly earnings report on Monday, August 5th.
According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($2.33) per share for the current financial year, with EPS estimates ranging from ($2.45) to ($2.18). For the next year, analysts anticipate that the company will report earnings of ($1.74) per share, with EPS estimates ranging from ($2.07) to ($1.55). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.05. Dynavax Technologies had a negative return on equity of 190.84% and a negative net margin of 1,156.11%. The business had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same quarter in the prior year, the business earned ($0.63) earnings per share. The company’s quarterly revenue was up 3294.1% compared to the same quarter last year.
Shares of Dynavax Technologies stock traded down $0.57 during trading hours on Friday, hitting $5.78. 5,268,048 shares of the company were exchanged, compared to its average volume of 1,101,828. Dynavax Technologies has a 1 year low of $5.12 and a 1 year high of $17.05. The company has a debt-to-equity ratio of 4.88, a current ratio of 5.27 and a quick ratio of 4.61. The stock has a market capitalization of $376.07 million, a PE ratio of -2.27 and a beta of 0.60.
In other Dynavax Technologies news, SVP Robert Coffman sold 63,202 shares of the company’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total value of $570,714.06. Following the sale, the senior vice president now owns 86,268 shares of the company’s stock, valued at $779,000.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP David Louis Johnson sold 20,765 shares of the company’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total value of $187,507.95. Following the completion of the sale, the vice president now directly owns 52,786 shares in the company, valued at approximately $476,657.58. The disclosure for this sale can be found here. Insiders sold 119,411 shares of company stock valued at $1,075,091 in the last quarter. 3.47% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Advisor Group Inc. grew its holdings in Dynavax Technologies by 515.3% in the fourth quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 3,746 shares during the last quarter. Quantamental Technologies LLC acquired a new stake in Dynavax Technologies in the first quarter valued at $62,000. M&T Bank Corp acquired a new stake in Dynavax Technologies in the first quarter valued at $78,000. Jefferies Group LLC grew its holdings in Dynavax Technologies by 27.7% in the first quarter. Jefferies Group LLC now owns 12,900 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 2,800 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in Dynavax Technologies by 56,326.1% in the first quarter. BNP Paribas Arbitrage SA now owns 12,978 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 12,955 shares during the last quarter. 85.78% of the stock is currently owned by institutional investors.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Recommended Story: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.